Implanet, a French spine and knee implant company, posted 4Q18 revenue of €1.5MM (USD 1.8MM), -21.5% vs. 4Q17, with 2018 revenue of €6.7MM (USD $8.0MM), -14.2% vs. 2017. The decline was primarily due to the decision to switch from a distributor model to direct sales in European spine markets, following successful use of this method in France and the U.S. Implanet now has a branch in the U.K., as well as a subsidiary in Germany, where the first surgery was performed in 4Q18. Sales of the Jazz spinal implant continued to grow in countries where the company operates directly, rising by 8% in France and 2% in the U.S.
Looking ahead to 2019, Implanet’s strategic plan is to:
- Continue implementation of direct sales in European markets
- Continue partnership with Kico Knee to distribute the Madison knee implant in the U.S. and Australia
- Finalize a commercial partnership to roll out the Jazz implant in the U.S. in 1Q19
- Halt sports medicine business as of end of 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows.
4Q18 | 4Q17 | $ Change | % Change | |
Knees | $0.8 | $0.8 | $0.0 | -5.4% |
Spine | $1.0 | $1.5 | -$0.5 | -30.4% |
Sports Medicine | $0.1 | $0.1 | $0.0 | -5.4% |
Total | $1.9 | $2.4 | -$0.5 | -20.9% |
FY18 | FY17 | $ Change | % Change | |
Knees | $2.9 | $3.5 | -$0.6 | -16.0% |
Spine | $5.0 | $5.8 | -$0.8 | -13.1% |
Sports Medicine | $0.3 | $0.3 | -$0.1 | -16.0% |
Total | $8.3 | $9.7 | -$1.4 | -14.3% |
Sources: Implanet; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Implanet, a French spine and knee implant company, posted 4Q18 revenue of €1.5MM (USD 1.8MM), -21.5% vs. 4Q17, with 2018 revenue of €6.7MM (USD $8.0MM), -14.2% vs. 2017. The decline was primarily due to the decision to switch from a distributor model to direct sales in European spine markets, following successful use of this method in France...
Implanet, a French spine and knee implant company, posted 4Q18 revenue of €1.5MM (USD 1.8MM), -21.5% vs. 4Q17, with 2018 revenue of €6.7MM (USD $8.0MM), -14.2% vs. 2017. The decline was primarily due to the decision to switch from a distributor model to direct sales in European spine markets, following successful use of this method in France and the U.S. Implanet now has a branch in the U.K., as well as a subsidiary in Germany, where the first surgery was performed in 4Q18. Sales of the Jazz spinal implant continued to grow in countries where the company operates directly, rising by 8% in France and 2% in the U.S.
Looking ahead to 2019, Implanet’s strategic plan is to:
- Continue implementation of direct sales in European markets
- Continue partnership with Kico Knee to distribute the Madison knee implant in the U.S. and Australia
- Finalize a commercial partnership to roll out the Jazz implant in the U.S. in 1Q19
- Halt sports medicine business as of end of 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows.
4Q18 | 4Q17 | $ Change | % Change | |
Knees | $0.8 | $0.8 | $0.0 | -5.4% |
Spine | $1.0 | $1.5 | -$0.5 | -30.4% |
Sports Medicine | $0.1 | $0.1 | $0.0 | -5.4% |
Total | $1.9 | $2.4 | -$0.5 | -20.9% |
FY18 | FY17 | $ Change | % Change | |
Knees | $2.9 | $3.5 | -$0.6 | -16.0% |
Spine | $5.0 | $5.8 | -$0.8 | -13.1% |
Sports Medicine | $0.3 | $0.3 | -$0.1 | -16.0% |
Total | $8.3 | $9.7 | -$1.4 | -14.3% |
Sources: Implanet; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.